Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry (2018) Witzel I, Laakmann E, Weide R, Neunhoeffer T, Park-Simon TJ, Schmidt M, Fasching P, et al. Journal article MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients (2018) Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, et al. Journal article The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab (2017) Tietze JK, Angelova D, Heppt MV, Reinholz M, Murphy WJ, Spannagl M, Ruzicka T, Berking C Journal article Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2017) Kuemmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, et al. Journal article Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) (2017) Loibl S, De La Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, et al. Journal article Adjvant HIPEC in gastric cancer patients with high risk of peritoneal carcinomatosis (2017) Aladashvili A, Croner R, Pantsulaia I Conference contribution Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma (2017) Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, et al. Journal article Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition (2017) Heppt MV, Heinzerling L, Kaehler KC, Forschner A, Kirchberger MC, Loquai C, Meissner M, et al. Journal article Prognostic factors and treatment outcomes in 444 patients with mucosal melanoma (2017) Heppt MV, Roesch A, Weide B, Gutzmer R, Meier F, Loquai C, Kaehler KC, et al. Journal article Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity (2017) Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, et al. Journal article